Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track MXCT with free AI briefings, catalyst countdowns, and dilution alerts.

MXCT · MaxCyte, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$132.7M Cash, Pro Forma
78.3mo Cash Runway
Follow MXCT by email Get an email when MXCT reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about MXCT, unsubscribe in one click. Privacy

📣 What MXCT Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Autologous Mesothelin-specific Human mRNA… Peritoneal Mesothelioma Phase 1 · NCT03608618 Terminated

Also used in these trials (approved or third-party drugs, not MXCT's own candidates): Cyclophosphamide.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

MXCT had $101.3M in cash and short-term investments on its Sep 30, 2026 balance sheet. Including the cash events since then, it holds about $132.7M pro forma, before operating spending after that date:

It burns about $5.1M/quarter from operations, an estimated runway of 78.3 months from Sep 30, 2026 at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MXCT files for a raise →

👥 Who Owns MXCT

Insiders 2.3% Institutions (150 holders) 65.8% Public and other holders 31.9%
HolderTypeShares% of sharesAs of
Capricorn Fund Managers Ltd Institution (13G, 5%+) 8,200,000 7.94% 2026-01-30
Maher Masoud
President and CEO, Director · +947,500 options
Insider 475,000 0.46% 2026-03-27
Stanley C Erck
Director · +100,369 options
Insider 428,749 0.42% 2026-06-17
Richard Douglas
Director · +100,369 options
Insider 260,998 0.25% 2026-06-17
John Joseph Johnston
Director · +117,786 options
Insider 201,581 0.20% 2026-06-17
Parmeet Ahuja
Chief Financial Officer · +375,000 options
Insider 187,500 0.18% 2026-04-15
William W Brooke
Director · +100,369 options
Insider 181,300 0.18% 2026-06-17
Douglas J Swirsky
CHIEF FINANCIAL OFFICER · +150,000 options
Insider 151,669 0.15% 2026-03-17
Cynthia Collins
Director · +100,369 options
Insider 111,310 0.11% 2026-06-17
Patrick J Balthrop
Director · +100,369 options
Insider 80,998 0.08% 2026-06-17
Yasir B. Al-Wakeel
Director · +100,369 options
Insider 80,998 0.08% 2026-06-17
Rekha Hemrajani
Director · +100,369 options
Insider 70,314 0.07% 2026-06-17

Share count 103,250,292 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full MXCT picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MXCT and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.